Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CLARINEX D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CLARINEX D 24 HOUR.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CLARINEX D 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination